Literature DB >> 16595050

Vaginal colonization with Candida spp. in human immunodeficiency virus-infected women: a cohort study.

Anna Beltrame1, Alberto Matteelli, Anna Cristina C Carvalho, Nuccia Saleri, Caterina Casalini, Susanna Capone, Andrea Patroni, Maria Manfrin, Giampiero Carosi.   

Abstract

We have conducted a longitudinal study on factors associated with candidal vaginal colonization, a precursor of vaginitis, in a cohort of HIV-infected women in Italy. All consecutive women attending a single, tertiary care clinical site were offered free screening for sexually transmitted infections and genital disorders every 6-12 months. Candidal vaginal colonization was defined as a positive culture for Candida spp. in an asymptomatic woman. From January 1998 to July 2002 we analysed 214 women. The baseline prevalence of candidal vaginal colonization was 16.8%. In the logistic regression analysis, the time since HIV infection > or =36 months (odds ratio [OR] = 0.18, 95% confidence interval [CI] 0.016-0.53, P = 0.002) and a plasma viral load > or =10,000 copies/mL (OR = 3.9, 95% CI 1.03-14.9, P = 0.045) were independently associated with candidal colonization. Among 130 women who were followed for a mean period of 24 months, the incidence of vaginal colonization was 10.7/100 women-years. In the Cox regression analysis, a CD4(+) T-lymphocytes count <100 cells/microL during the follow-up was associated with an increased risk of candidal vaginal colonization (OR = 4.45, C.I. = 1.20-16.81, P = 0.03). Risk of candidal vaginal colonization episodes in HIV-infected women significantly increase when CD4(+) T-lymphocytes are less than 100.

Entities:  

Mesh:

Year:  2006        PMID: 16595050     DOI: 10.1258/095646206776253435

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  6 in total

1.  Hosting infection: experimental models to assay Candida virulence.

Authors:  Donna M Maccallum
Journal:  Int J Microbiol       Date:  2011-12-22

2.  Antimicrobial effects of liquid anesthetic isoflurane on Candida albicans.

Authors:  Viachaslau M Barodka; Edward Acheampong; Garry Powell; Ludmila Lobach; David A Logan; Zahida Parveen; Valerie Armstead; Muhammad Mukhtar
Journal:  J Transl Med       Date:  2006-11-09       Impact factor: 5.531

3.  Effect of highly active antiretroviral therapy on vaginal Candida spp. isolation in HIV-infected compared to HIV-uninfected women.

Authors:  Silvia de Souza Dantas Alczuk; Patrícia de Souza Bonfim-Mendonça; Sheila Cristina Rocha-Brischiliari; Cristiane Suemi Shinobu-Mesquita; Helen Priscilla Rodrigues Martins; Fabrícia Gimenes; André Luelsdorf Pimenta de Abreu; Maria Dalva de Barros Carvalho; Sandra Marisa Pelloso; Terezinha Inez Estivalet Svidzinski; Marcia Edilaine Lopes Consolaro
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2015 Mar-Apr       Impact factor: 1.846

4.  Rethinking T cell immunity in oropharyngeal candidiasis.

Authors:  Liise-anne Pirofski; Arturo Casadevall
Journal:  J Exp Med       Date:  2009-02-09       Impact factor: 14.307

5.  Determinants of symptomatic vulvovaginal candidiasis among human immunodeficiency virus type 1 infected women in rural KwaZulu-Natal, South Africa.

Authors:  Teke Apalata; William H Carr; Willem A Sturm; Benjamin Longo-Mbenza; Prashini Moodley
Journal:  Infect Dis Obstet Gynecol       Date:  2014-04-09

6.  Vulvovaginal candidiasis: species distribution of Candida and their antifungal susceptibility pattern.

Authors:  Adane Bitew; Yeshiwork Abebaw
Journal:  BMC Womens Health       Date:  2018-06-15       Impact factor: 2.809

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.